Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EOM Pharmaceutical Holdings's ROE % for the quarter that ended in Jun. 2018 was -34.60%. EOM Pharmaceutical Holdings's PB Ratio for the quarter that ended in Jun. 2018 was 3.18.
EOM Pharmaceutical Holdings's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2018 was -10.88%.
EOM Pharmaceutical Holdings ROE % Adjusted to Book Value Related Terms
EOM Pharmaceutical Holdings ROE % Adjusted to Book Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EOM Pharmaceutical Holdings ROE % Adjusted to Book Value Chart
IMUC vs MNTMD, RTTR, BZYR: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, EOM Pharmaceutical Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EOM Pharmaceutical Holdings ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where EOM Pharmaceutical Holdings's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -10.88% mean?
EOM Pharmaceutical Holdings (IMUC) has a ROE % Adjusted to Book Value of -10.88% as of Jun. 2018. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' ROE % Adjusted to Book Value too high?
EOM Pharmaceutical Holdings' current ROE % Adjusted to Book Value is -10.88%.
How does EOM Pharmaceutical Holdings' ROE % Adjusted to Book Value compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' ROE % Adjusted to Book Value of -10.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current ROE % Adjusted to Book Value is -10.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current ROE % Adjusted to Book Value of -10.88%. The current ROE % Adjusted to Book Value is -10.88%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current ROE % Adjusted to Book Value is -10.88% as of Jun. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMUC has been successfully added to your 
